What Are NAD+ Precursors?

The precursor family, at a glance

NAD+ precursors are molecules the body can convert into NAD+ through its natural biosynthetic pathways. The four most commonly discussed in research and in the supplement market are niacin (nicotinic acid), nicotinamide, nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN).[1][2] They enter NAD+ metabolism at different points: niacin feeds the Preiss–Handler pathway, while nicotinamide, NR, and NMN all feed into the salvage pathway, with NR converted into NMN and NMN converted into NAD+.[1][2]

Why not just take NAD+ itself?

As covered on this hub’s page about NAD+, the coenzyme itself is a relatively large molecule, which is the main biochemical reason most research and most products work with smaller precursor molecules instead.[2]

NMN and NR: the two most-studied precursors

Of the four precursors, NMN and NR currently have the most published human clinical research behind them.[1] Novera has published a dedicated, sourced comparison of NMN, NR, and NAD+ that covers this ground in detail, including a table of published human research.

Niacin and nicotinamide: the vitamin B3 forms

Niacin and nicotinamide are both established forms of vitamin B3, with their own long, separate research histories distinct from NAD+ precursor research specifically. See NMN vs. Niacin & Nicotinamide for a full, sourced comparison of how these related B3 molecules differ in evidence base, dosing history, and established medical use.

Comparing the evidence base

Because these four molecules differ in structure, dose, and how much human research exists for each, claims that flatly declare one precursor “better” than another should be read carefully. Evaluating any such claim means asking what specific outcome was measured, in what population, at what dose, and for how long — not simply which molecule sounds newer or is marketed most heavily.